Press Releases

KRRO-110 is the first RNA editing oligonucleotide candidate from Korro’s proprietary OPERA™ platform Korro has demonstrated the ability to repair the misfolding of the Alpha-1 Antitrypsin (A1AT) protein containing the Z mutation, as well as reduce liver aggregates, in a preclinical mouse model

Biotech veteran brings more than two decades of life science experience to Korro’s Board CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent

Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fund operations into 2026 Funds multiple potentially value-creating milestones, including advancing its lead product candidate in Alpha-1 antitrypsin

Tim Pearson, CEO of Carrick Therapeutics and ex-CFO of TESARO, will join as Director contingent on the close of the proposed merger with Frequency Todd Chappell is elevated to role of Chief Operating Officer, bringing over 20 years of product development and product strategy experience Proposed

Merger to create a  Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase of normal A1AT

CAMBRIDGE, Mass., May 10, 2023 —  Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Shelby Walker, JD, as Senior Vice President and General Counsel. In this new role, Ms.

Collaboration to combine Korro’s RNA editing technology and Genevant’s LNP technology CAMBRIDGE, Mass., VANCOUVER, British Columbia, and BASEL, Switzerland, March 7, 2023  – Korro Bio, a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Genevant

CAMBRIDGE, Mass., February 28, 2023 —  Korro Bio, Inc ., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Steve Colletti, Ph.D. as Chief Scientific Officer. Dr. Colletti is a highly respected scientist and seasoned

CAMBRIDGE, Mass., January 4, 2023  — Korro Bio, Inc. , a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer and President, will present at the 41 st  Annual J.P.

Venkat Krishnamurthy appointed Senior Vice President, Head of Platform Stephanie Engels appointed Senior Vice President, Head of People and Culture CAMBRIDGE, Mass., November 8, 2022— Korro Bio, Inc ., a leading RNA editing company focused on the discovery and development of novel genetic